William Blair & Company
NTLA icon

William Blair & Company’s Intellia Therapeutics NTLA Stock Holding History

William Blair & Company’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.58M Buy
152,612
+134,402
+738% +$1.88M 0.01% 696
2026
Q1 		$233K Buy
18,210
+50
+0.3% +$637 ﹤0.01% 1421
2025
Q4 		$163K Sell
18,160
-2,000
-10% -$27.5K ﹤0.01% 1502
2025
Q3 		$348K Buy
+20,160
New +$248K ﹤0.01% 1256
2024
Q2 		– Sell
-10,307
Closed -$284K – 1860
2024
Q1 		$284K Buy
10,307
+57
+0.6% +$1.58K ﹤0.01% 1276
2023
Q4 		$313K Buy
10,250
+1,000
+11% +$28.7K ﹤0.01% 1234
2023
Q3 		$292K Hold
9,250
– – ﹤0.01% 1245
2023
Q2 		$377K Buy
9,250
+2,000
+28% +$81.1K ﹤0.01% 1158
2023
Q1 		$270K Sell
7,250
-110
-1% -$4.31K ﹤0.01% 1283
2022
Q4 		$257K Sell
7,360
-3,178
-30% -$151K ﹤0.01% 1284
2022
Q3 		$590K Buy
10,538
+178
+2% +$11K ﹤0.01% 984
2022
Q2 		$536K Sell
10,360
-2
-0% -$102 ﹤0.01% 1041
2022
Q1 		$753K Buy
10,362
+1,100
+12% +$93.2K ﹤0.01% 1020
2021
Q4 		$1.09M Buy
9,262
+152
+2% +$19K ﹤0.01% 923
2021
Q3 		$1.22M Hold
9,110
– – ﹤0.01% 853
2021
Q2 		$1.48M Hold
9,110
– – 0.01% 805
2021
Q1 		$731K Buy
9,110
+1,000
+12% +$67.1K ﹤0.01% 1002
2020
Q4 		$441K Buy
+8,110
New +$295K ﹤0.01% 1118
2019
Q4 		– Sell
-19,730
Closed -$263K – 1779
2019
Q3 		$263K Hold
19,730
– – ﹤0.01% 1174
2019
Q2 		$323K Sell
19,730
-2,530
-11% -$39.8K ﹤0.01% 1130
2019
Q1 		$380K Buy
22,260
+200
+0.9% +$2.98K ﹤0.01% 1056
2018
Q4 		$301K Buy
22,060
+12,060
+121% +$224K ﹤0.01% 1081
2018
Q3 		$286K Sell
10,000
-6,000
-38% -$175K ﹤0.01% 1157
2018
Q2 		$438K Buy
+16,000
New +$388K ﹤0.01% 986

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

William Blair & Company's NTLA Position: Q2 2026 in Review

William Blair & Company increased its Intellia Therapeutics (NTLA) stake by 738% in Q2 2026, buying an estimated $1.88M and bringing the position to 152,612 shares worth $2.58M. The position accounts for 0.01% of the portfolio, ranked #696.

William Blair & Company first reported a position in NTLA in Q2 2018 and has held it in 24 quarters since. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • William Blair & Company held 152,612 shares of Intellia Therapeutics worth $2.58M as of Q2 2026.
  • William Blair & Company bought 134,402 Intellia Therapeutics shares in Q2 2026, an estimated $1.88M.
  • Intellia Therapeutics made up 0.01% of William Blair & Company's portfolio in Q2 2026, its #696 holding.
  • William Blair & Company first reported a position in Intellia Therapeutics in Q2 2018 and has held it in 24 quarters since.
  • 328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on William Blair & Company's 13F filing for Q2 2026, filed 11 Aug 2026.